Baqsimi FDA Approval History
Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycemia in diabetes patients ages 4 years and older.
Development Timeline for Baqsimi
|Jul 24, 2019||ApprovalFDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.